Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Go Back to All Clinical Trials

Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Brief description of study

Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors

Clinical Study Identifier: s23-00360

ClinicalTrials.gov Identifier: NCT05732831

Principal Investigator: Salman Rafi Punekar.

Other Investigators: Nila Theresa De La Rosa, Joshua K Sabari, Samantha VanMaanen, Eneil De La Pena, Jessica Wang, Elaine Shum, Nina Beri, Kristen Spencer, Douglas K Marks, Scot Niglio, Keriann M Scavone, Kathleen M Madden, Nancy Chan, Caitlin Elizabeth Ryan, Kirby Rodriguez, Janice Mehnert, Vamsidhar Velcheti.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies